474 related articles for article (PubMed ID: 25026211)
1. Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.
Li W; Cooper J; Zhou L; Yang C; Erdjument-Bromage H; Zagzag D; Snuderl M; Ladanyi M; Hanemann CO; Zhou P; Karajannis MA; Giancotti FG
Cancer Cell; 2014 Jul; 26(1):48-60. PubMed ID: 25026211
[TBL] [Abstract][Full Text] [Related]
2. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus.
Li W; You L; Cooper J; Schiavon G; Pepe-Caprio A; Zhou L; Ishii R; Giovannini M; Hanemann CO; Long SB; Erdjument-Bromage H; Zhou P; Tempst P; Giancotti FG
Cell; 2010 Feb; 140(4):477-90. PubMed ID: 20178741
[TBL] [Abstract][Full Text] [Related]
3. Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4 (DCAF1).
Li W; Giancotti FG
Cell Cycle; 2010 Nov; 9(22):4433-6. PubMed ID: 21084862
[TBL] [Abstract][Full Text] [Related]
4. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
5. Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression.
Cooper J; Li W; You L; Schiavon G; Pepe-Caprio A; Zhou L; Ishii R; Giovannini M; Hanemann CO; Long SB; Erdjument-Bromage H; Zhou P; Tempst P; Giancotti FG
Sci Signal; 2011 Aug; 4(188):pt6. PubMed ID: 21878678
[TBL] [Abstract][Full Text] [Related]
6. BRCA1/BARD1-dependent ubiquitination of NF2 regulates Hippo-YAP1 signaling.
Verma S; Yeddula N; Soda Y; Zhu Q; Pao G; Moresco J; Diedrich JK; Hong A; Plouffe S; Moroishi T; Guan KL; Verma IM
Proc Natl Acad Sci U S A; 2019 Apr; 116(15):7363-7370. PubMed ID: 30918126
[TBL] [Abstract][Full Text] [Related]
7. The Hippo pathway member Nf2 is required for inner cell mass specification.
Cockburn K; Biechele S; Garner J; Rossant J
Curr Biol; 2013 Jul; 23(13):1195-201. PubMed ID: 23791728
[TBL] [Abstract][Full Text] [Related]
8. Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway.
Li Y; Zhou H; Li F; Chan SW; Lin Z; Wei Z; Yang Z; Guo F; Lim CJ; Xing W; Shen Y; Hong W; Long J; Zhang M
Cell Res; 2015 Jul; 25(7):801-17. PubMed ID: 26045165
[TBL] [Abstract][Full Text] [Related]
9. WWC1 and NF2 Prevent the Development of Intrahepatic Cholangiocarcinoma by Regulating YAP/TAZ Activity through LATS in Mice.
Park J; Kim JS; Nahm JH; Kim SK; Lee DH; Lim DS
Mol Cells; 2020 May; 43(5):491-499. PubMed ID: 32451369
[TBL] [Abstract][Full Text] [Related]
10. The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors.
Zhou L; Lyons-Rimmer J; Ammoun S; Müller J; Lasonder E; Sharma V; Ercolano E; Hilton D; Taiwo I; Barczyk M; Hanemann CO
Oncogene; 2016 Jun; 35(26):3443-53. PubMed ID: 26549023
[TBL] [Abstract][Full Text] [Related]
11. Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses
Cooper J; Xu Q; Zhou L; Pavlovic M; Ojeda V; Moulick K; de Stanchina E; Poirier JT; Zauderer M; Rudin CM; Karajannis MA; Hanemann CO; Giancotti FG
Mol Cancer Ther; 2017 Aug; 16(8):1693-1704. PubMed ID: 28468780
[TBL] [Abstract][Full Text] [Related]
12. Lipid kinase PIP5Kα contributes to Hippo pathway activation via interaction with Merlin and by mediating plasma membrane targeting of LATS1.
Le TPH; Nguyen NTT; Le DDT; Anwar MA; Lee SY
Cell Commun Signal; 2023 Jun; 21(1):149. PubMed ID: 37337213
[TBL] [Abstract][Full Text] [Related]
13. NEDD4L-mediated Merlin ubiquitination facilitates Hippo pathway activation.
Wei Y; Yee PP; Liu Z; Zhang L; Guo H; Zheng H; Anderson B; Gulley M; Li W
EMBO Rep; 2020 Dec; 21(12):e50642. PubMed ID: 33058421
[TBL] [Abstract][Full Text] [Related]
14. β1 integrin-dependent Rac/group I PAK signaling mediates YAP activation of Yes-associated protein 1 (YAP1) via NF2/merlin.
Sabra H; Brunner M; Mandati V; Wehrle-Haller B; Lallemand D; Ribba AS; Chevalier G; Guardiola P; Block MR; Bouvard D
J Biol Chem; 2017 Nov; 292(47):19179-19197. PubMed ID: 28972170
[TBL] [Abstract][Full Text] [Related]
15. Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.
Miyanaga A; Masuda M; Tsuta K; Kawasaki K; Nakamura Y; Sakuma T; Asamura H; Gemma A; Yamada T
J Thorac Oncol; 2015 May; 10(5):844-851. PubMed ID: 25902174
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
17. Merlin/NF2-Lin28B-let-7 Is a Tumor-Suppressive Pathway that Is Cell-Density Dependent and Hippo Independent.
Hikasa H; Sekido Y; Suzuki A
Cell Rep; 2016 Mar; 14(12):2950-61. PubMed ID: 26997273
[TBL] [Abstract][Full Text] [Related]
18. RAC-LATS1/2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3.
Jang JW; Kim MK; Lee YS; Lee JW; Kim DM; Song SH; Lee JY; Choi BY; Min B; Chi XZ; Bae SC
Oncogene; 2017 Feb; 36(7):999-1011. PubMed ID: 27425596
[TBL] [Abstract][Full Text] [Related]
19. Merlin, a multi-suppressor from cell membrane to the nucleus.
Zhou L; Hanemann CO
FEBS Lett; 2012 May; 586(10):1403-8. PubMed ID: 22595235
[TBL] [Abstract][Full Text] [Related]
20. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
